Albireo Pharma (NASDAQ:ALBO) Given a $69.00 Price Target at Wedbush

Wedbush set a $69.00 price objective on Albireo Pharma (NASDAQ:ALBO) in a report released on Thursday, Stock Target Advisor reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

ALBO has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Hess Midstream Partners from a hold rating to a sell rating in a research report on Tuesday, May 14th. HC Wainwright restated a buy rating and set a $60.00 price target on shares of Beyondspring in a report on Wednesday. Cowen restated a market perform rating and set a $99.00 price target (up from $97.00) on shares of United Continental in a report on Wednesday, April 17th. William Blair restated an outperform rating on shares of Albireo Pharma in a report on Thursday, May 9th. Finally, ValuEngine cut Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $54.25.

ALBO traded down $1.00 on Thursday, hitting $28.44. 1,204 shares of the stock were exchanged, compared to its average volume of 69,676. Albireo Pharma has a 12 month low of $19.10 and a 12 month high of $38.69. The company has a 50-day moving average of $32.27. The firm has a market capitalization of $370.93 million, a price-to-earnings ratio of -7.26 and a beta of 1.56.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.37) by ($0.02). Albireo Pharma had a negative return on equity of 47.03% and a negative net margin of 2,900.81%. The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $1.20 million. Equities analysts anticipate that Albireo Pharma will post -5.99 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its stake in shares of Albireo Pharma by 40.2% in the 4th quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock valued at $320,000 after purchasing an additional 3,743 shares during the last quarter. Prudential Financial Inc. increased its holdings in shares of Albireo Pharma by 5.6% in the 4th quarter. Prudential Financial Inc. now owns 26,556 shares of the biopharmaceutical company’s stock valued at $652,000 after acquiring an additional 1,404 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Albireo Pharma by 7.2% in the 4th quarter. Bank of New York Mellon Corp now owns 37,552 shares of the biopharmaceutical company’s stock valued at $921,000 after acquiring an additional 2,529 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Albireo Pharma by 40.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 116,223 shares of the biopharmaceutical company’s stock valued at $2,850,000 after acquiring an additional 33,390 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Albireo Pharma by 11.3% in the 4th quarter. Geode Capital Management LLC now owns 97,434 shares of the biopharmaceutical company’s stock valued at $2,390,000 after acquiring an additional 9,922 shares during the period. Hedge funds and other institutional investors own 70.41% of the company’s stock.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Further Reading: How does the Beige Book influence monetary policy?

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.